This Review discusses the rapidly accumulating preclinical evidence in support of antitumour, but also of some pro-tumour, roles for γδ T cells in cancer progression. It also outlines the potential for manipulating their functions for use as an unconventional form of cancer immunotherapy.
- Bruno Silva-Santos
- Sofia Mensurado
- Seth B. Coffelt